🔗 Share this article

While the United States undertakes unprecedented changes to its immunization recommendations, an unexpected name has emerged unexpectedly: Dr. Tracy Beth Høeg, a Danish American sports physician and epidemiologist who rose to prominence by questioning coronavirus shots in the pandemic and has zeroed in on possible deaths following COVID-19 immunization in her short time at the US Food and Drug Administration (FDA).

Proposed Changes to Childhood Vaccine Schedule

Agency leaders were set to reveal major revisions to the childhood immunization program earlier this month, bringing the US with the Danish vaccine program, sources say – a significant shift that would put the US at odds with many the international standard with no evidence for public health gain. The announcement has been delayed until the next year.

In place of Vinay Prasad, Høeg is scheduled to speak at the event. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the office this year.

Consolidating Power at the FDA

The acting appointment could signify a tighter collaboration between the pharmaceutical and biologics divisions as Høeg and Prasad strengthen their influence at the FDA – and it signals a renewed priority upon dismantling previously authorized vaccines at the FDA.

Dr. Høeg has often pushed for ending some pediatric shot schedules in the US to become more in line with the Danish model, a society with nationalized medicine and a number of inhabitants roughly the population of Wisconsin’s.

To date public appearances, she has continued to focus on vaccination policy – usually the domain of Dr. Prasad, director of the FDA’s vaccine center – instead of drug regulation.

Concerns Over Expertise

The appointee has no obvious experience in pharmaceutical research, oversight or administrative roles, which has been customary for former heads of the CBER. She has served at the FDA as a senior adviser to the commissioner and CBER since March.

“She doesn’t seem to have any of the qualifications” for overseeing the CDER, said Jonathan Howard. “She’s never run a clinical trial. She lacks experience in managing a sizeable institution. She lacks background in drug approvals.”

Past commissioners of CBER would “be deeply familiar with regulatory frameworks and the underlying principles of medication creation”, commented a former acting FDA commissioner. “Clearly, she has not acquired the kind of background that previous people who led CBER have had.”

The drug center has an vast workload at the agency, she emphasized.

“Everybody just pays attention on the new drug program, but the generic program authorizes numerous generic drugs. There is also a biosimilars division, non-prescription drug unit and so forth, and each of these must be managed,” she explained. “The thing you don’t keep your eye on, that is precisely what that I always told people is going to cause problems.”

There is also, a significant management aspect to the job, which supervises in excess of 5,000 staff members. “It is a enormous management job, if you do it right,” the former official said.

Official Statement and Disputed Programs

When asked about concerns about Høeg’s qualifications and whether this assignment represents more teamwork among agency officials on vaccines, a spokesperson said that the “inquiries are based on incorrect presumptions”.

“Her experience is consistent with the functions of her position,” the representative explained, noting the time Høeg spent advising the FDA commissioner on “pharmaceutical safety and regulatory science, including computerized risk analysis and vaccine surveillance”.

In her interim role, Høeg assumes responsibility for the agency head's recently launched priority voucher program, a contentious expedited medication authorization process that allegedly worried her former heads. “How are these therapies being chosen for this voucher program? Who makes the calls?” Howard asked. “There is a lot of secrecy going on at the regulatory body right now.”

Overall, he stated, “the Food and Drug Administration appears to be shifting towards more relaxed rules of most medications, except for shots.”

Documented History on Vaccines

Concerning vaccines, Dr. Høeg has a more established, if troubling, track record, some experts observe. She authored a research paper using unconfirmed volunteer-provided data to assess the incidence of heart inflammation following Covid vaccination. She counseled the Florida surgeon general Dr. Joseph Ladapo, who reportedly have changed statistics to suggest COVID-19 vaccines are riskier than they are.

Among her “policy goals” for the current federal leadership encompassed altering regulations for new vaccines and discontinuing “non-essential” immunizations, she said following the vote on a podcast. At the agency, Dr. Høeg has reportedly floated the idea of barring young men from getting Covid vaccinations.

“She is an all-around dogmatist who starts off with her preconceived notions and works backwards to retrofit the science in a extremely misleading, dishonest fashion,” Howard stated.

Taking Control and a “Campaign of Retribution”

Høeg aligned with fellow dissenters, {like|